These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 6914040)

  • 21. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
    Newman-Tancredi A; Cussac D; Quentric Y; Touzard M; Verrièle L; Carpentier N; Millan MJ
    J Pharmacol Exp Ther; 2002 Nov; 303(2):815-22. PubMed ID: 12388668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
    Furukawa Y; Filiano JJ; Kish SJ
    Mov Disord; 2004 Oct; 19(10):1256-8. PubMed ID: 15389992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Successful use of amantadine in treatment of malignant neuroleptic syndrome].
    Blümlein G
    Psychiatr Prax; 1997 Sep; 24(5):257-8. PubMed ID: 9417555
    [No Abstract]   [Full Text] [Related]  

  • 24. Toxic corneal oedema associated with amantadine use.
    Pond A; Lee MS; Hardten DR; Harrison AR; Krachmer JH
    Br J Ophthalmol; 2009 Mar; 93(3):281, 413. PubMed ID: 19244027
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of Parkinson's disease.
    Eadie MJ
    Aust Fam Physician; 1995 Sep; 24(9):1685-7, 1690-2. PubMed ID: 7487655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amantadine in the akinetic-rigid variant of Huntington's disease.
    Magnet MK; Bonelli RM; Kapfhammer HP
    Ann Pharmacother; 2004; 38(7-8):1194-6. PubMed ID: 15178736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease.
    Anglès A; Bagheri H; Saivin S; Montastruc JL
    Therapie; 2002; 57(4):408-10. PubMed ID: 12422563
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of amantadine in essential tremor: a randomized, placebo-controlled trial.
    Gironell A; Kulisevsky J; Pascual-Sedano B; Flamarich D
    Mov Disord; 2006 Apr; 21(4):441-5. PubMed ID: 16229019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
    Cersósimo MG; Scorticati MC; Micheli FE
    Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Visual impairment in Parkinson's disease treated with amantadine: case report and review of the literature.
    Kubo S; Iwatake A; Ebihara N; Murakami A; Hattori N
    Parkinsonism Relat Disord; 2008; 14(2):166-9. PubMed ID: 17509924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amantadine-induced serotonin syndrome in a patient with renal failure.
    Cheng PL; Hung SW; Lin LW; Chong CF; Lau CI
    Am J Emerg Med; 2008 Jan; 26(1):112.e5-6. PubMed ID: 18082803
    [No Abstract]   [Full Text] [Related]  

  • 32. Twenty-five years of amantadine therapy in Parkinson's disease.
    Danielczyk W
    J Neural Transm Suppl; 1995; 46():399-405. PubMed ID: 8821075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
    Montastruc JL; Schmitt L; Bagheri H
    Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Corneal endothelial dysfunction associated with amantadine toxicity.
    Chang KC; Kim MK; Wee WR; Lee JH
    Cornea; 2008 Dec; 27(10):1182-5. PubMed ID: 19034138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: report of a case series.
    Singer C; Papapetropoulos S; Gonzalez MA; Roberts EL; Lieberman A
    Mov Disord; 2005 Jul; 20(7):873-7. PubMed ID: 15809995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possible new mechanism for the antiparkinsonian effect of amantadine.
    Bennett VL; Juorio AV; Li XM
    J Psychiatry Neurosci; 1999 Jan; 24(1):52-3. PubMed ID: 9987209
    [No Abstract]   [Full Text] [Related]  

  • 37. [Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient].
    Ceballos-Baumann AO
    MMW Fortschr Med; 2002 May; Suppl 2():37-43. PubMed ID: 12070848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The response of "de novo" Parkinson's disease patients to bromocriptine in a "low and slow" regimen is predictive for prognosis.
    Sampaio C; Coelho T; Castro-Caldas A; Bastos-Lima A; Levy A
    J Neural Transm Suppl; 1995; 45():197-202. PubMed ID: 8748626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bromocriptine is ineffective in the treatment of chronic nonfluent aphasia.
    Ozeren A; Sarica Y; Mavi H; Demirkiran M
    Acta Neurol Belg; 1995 Dec; 95(4):235-8. PubMed ID: 8553797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amantadine: an antiparkinsonian agent inhibits bovine brain 60 kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme.
    Kakkar R; Raju RV; Rajput AH; Sharma RK
    Brain Res; 1997 Feb; 749(2):290-4. PubMed ID: 9138729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.